4174.TWO

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2027	$81M	—	$-8.94	$-8.94–$-8.94	—	1
2028	$1M	-98.8%	$-6.60	$-6.60–$-6.60	—	1
2029	$111M	+11008.5%	$-7.63	$-7.63–$-7.63	—	1
2030	$130M	+17.4%	$-6.56	$-6.56–$-6.56	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 1 of the last 4 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-12	$-8.83	$-1.50	+83.0%
2026-05-12	$36.86	$-3.35	-109.1%
2026-03-09	$-5.14	$-18.80	-265.8%
2025-09-30	$-2.75	$-3.56	-29.5%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
4174.TWOOBI Pharma, Inc.	$26.65	+2.50%	$3.5B	—
1734.TWSinphar Pharmaceutical Co. Ltd.	$31.30	+0.00%	$6.3B	—
1760.TWPanion & Bf Biotech Inc.	$53.60	-0.37%	$4.6B	—
4157.TWOTaiGen Biopharmaceuticals Holdings Limited	$8.95	+2.99%	$6.4B	—
4162.TWOPharmaEngine, Inc.

OBI Pharma, Inc.

OBI Pharma, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing cutting-edge therapies for critical medical needs, specifically in the field of cancer, with operations spanning Taiwan and international markets. The company's extensive product pipeline features numerous advanced treatment candidates. These include Adagloxad Simolenin (OBI-822), an active immunity drug for breast cancer designed to stimulate antibody production against the tumor carbohydrate antigen Globo H; OBI-833, an immunity-boosting anti-cancer agent targeting lung cancer; OBI-866 SSEA-4, another active immune-oncology medication; and OBI-888, a passive immunotherapy monoclonal antibody also developed to confront Globo H. Additionally, their portfolio contains OBI-999, an antibody-drug conjugate; OBI-3424, a small-molecule chemotherapy prodrug; OBI-858, a botulinum toxin; and other investigational drugs such as OBI-898 and OBI-998. Founded in 2002, the enterprise is headquartered in Taipei, Taiwan.

www.obipharma.com

Employees: 260
IPO / List date: Dec 12, 2012
HQ: TW

Held by traders on TradeandTell

No one on the platform currently holds 4174.TWO.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in 4174.TWO as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded 4174.TWO yet.